A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia
NCT06285825 is a phase 2 interventional trial sponsored by M.D. Anderson Cancer Center. As of 21 Nov 2026, it is recruiting participants. It studies Emapalumab in Cytopenia. The registry lists an enrollment of 32 participants at 1 site in 1 country. The registry lists a start date of 5 Jul 2024 and a primary completion date of 22 Aug 2028.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT06285825 |
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | M.D. Anderson Cancer Center |
| Enrollment | 32 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Cytopenia |
| Drugs | Emapalumab |
| Start | 5 Jul 2024 |
| Primary completion | 22 Aug 2028 |
| Study completion | 22 Aug 2028 |
| Last update posted | 7 Aug 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Paolo Strati, MD
M.D. Anderson Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Md Anderson Cancer Center
Houston
Paolo Strati, MDRecruiting
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT06285825
Each answer restates registry values shown on this page.
What is NCT06285825?
NCT06285825 is a phase 2 interventional trial sponsored by M.D. Anderson Cancer Center. It studies Emapalumab in Cytopenia.
Is NCT06285825 recruiting?
As of 21 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.
Who leads NCT06285825?
The registry names Paolo Strati, MD (principal investigator, M.D. Anderson Cancer Center) as the overall official.
Where does NCT06285825 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT06285825 study?
The registered drug and biological interventions are Emapalumab.
When is NCT06285825 expected to complete?
The registry lists a primary completion date of 22 Aug 2028 and a study completion date of 22 Aug 2028. The sponsor last updated the record on 7 Aug 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.